Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
00:52:14 EDT Sat 18 Apr 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:ZVRA from 2025-04-18 to 2026-04-17 - 35 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-03-20 16:30U:ZVRANews ReleaseZevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4)
2026-03-16 07:30U:ZVRANews ReleaseZevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million
2026-03-09 16:05U:ZVRANews ReleaseZevra Reports Fourth Quarter and Full Year 2025 Financial Results
2026-03-05 07:30U:ZVRANews ReleaseZevra Therapeutics Appoints Justin Renz as Chief Financial Officer
2026-03-02 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call
2026-02-25 07:30U:ZVRANews ReleaseZevra Therapeutics to Present at the Citizens Life Sciences Conference
2026-02-04 07:30U:ZVRANews ReleaseZevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA(TM) in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium(TM)
2026-02-02 07:30U:ZVRANews ReleaseZevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026
2026-01-26 07:30U:ZVRANews ReleaseZevra Therapeutics to Present Multiple Analyses on MIPLYFFA(TM) at the 22nd Annual WORLDSymposium(TM)
2026-01-08 07:30U:ZVRANews ReleaseZevra Therapeutics to Present at the J.P. Morgan 44th Annual Healthcare Conference
2025-12-29 07:30U:ZVRANews ReleaseZevra Therapeutics Executes Distribution Agreement to Broaden Access to MIPLYFFA(TM) for the Treatment of Niemann-Pick Disease Type C (NPC)
2025-12-12 16:30U:ZVRANews ReleaseZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 07:30U:ZVRANews ReleaseZevra Therapeutics, Inc. Appoints Alicia Secor to Board of Directors; Announces Retirement of Wendy Dixon, PhD
2025-11-20 16:05U:ZVRANews ReleaseZevra Therapeutics, Inc. Announces CFO Transition
2025-11-05 16:05U:ZVRANews ReleaseZevra Reports Third Quarter 2025 Financial Results and Corporate Update
2025-10-29 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate in the Guggenheim Healthcare Innovation Conference
2025-10-27 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q3 2025 Financial Results Call
2025-10-06 17:51U:ZVRANews ReleaseZevra Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
2025-09-18 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Upcoming Oral Presentation at the International Niemann-Pick Disease Alliance (INPDA) Meeting and Poster Presentations at the Child Neurology Society (CNS) Conference on MIPLYFFA(TM) (arimoclomol) and OLPRUVA(TM) (sodium pheny
2025-09-04 07:30U:ZVRANews ReleaseZevra Therapeutics Presents Positive New Data Supporting Foundational Role of MIPLYFFA(TM) (arimoclomol) for the Treatment of Niemann-Pick Disease Type C at the International Congress of Inborn Errors of Metabolism (ICIEM)
2025-08-28 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Multiple Datasets on MIPLYFFA(TM) (arimoclomol) to be Presented at the International Congress of Inborn Errors of Metabolism (ICIEM)
2025-08-26 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate at Upcoming Investor Conferences in September
2025-08-12 16:05U:ZVRANews ReleaseZevra Reports Second Quarter 2025 Financial Results and Corporate Update
2025-08-06 07:30U:ZVRANews ReleaseZevra Therapeutics to Participate in the Canaccord Genuity 45th Annual Growth Conference
2025-08-04 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q2 2025 Financial Results Call
2025-07-28 06:00U:ZVRANews ReleaseZevra Therapeutics Submits Marketing Authorization Application to European Medicines Agency to Review Arimoclomol for the Treatment of Niemann-Pick Disease Type C
2025-07-18 07:30U:ZVRANews ReleaseZevra Therapeutics Announces MIPLYFFA(TM) and OLPRUVA(TM) Presentations at the Annual Meeting of the Southeastern Regional Genetics Group (SERGG)
2025-07-16 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Open Label Extension Data Showing Sustained Long-Term Efficacy of MIPLYFFA for the Treatment of NPC Published in the Journal of Molecular Genetics and Metabolism
2025-07-11 07:30U:ZVRANews ReleaseZevra Therapeutics Announces MIPLYFFA(TM) (arimoclomol) Featured in Presentations at the National Niemann Pick Disease Foundation Conference
2025-05-29 16:36U:ZVRANews ReleaseZevra Announces Final Results of 2025 Annual Meeting of Stockholders
2025-05-21 07:30U:ZVRANews ReleaseAll Three Leading Proxy Advisory Firms - ISS, Glass Lewis, and Egan-Jones - Recommend Zevra Stockholders Vote FOR the Company's Director Nominees
2025-05-13 16:05U:ZVRANews ReleaseZevra Reports First Quarter 2025 Financial Results and Corporate Update
2025-05-06 07:30U:ZVRANews ReleaseZevra Therapeutics Announces Details for Q1 2025 Financial Results Call
2025-05-01 16:05U:ZVRANews ReleaseZevra Therapeutics to Participate in the Citizens Life Science Conference
2025-04-21 07:22U:ZVRANews ReleaseZevra Files Definitive Proxy Statement and Mails Letter to Stockholders